Optimal management of taxane acute pain syndrome not clear
the ONA take:
Despite its prevalence in patients receiving taxane-based chemotherapies, taxane acute pain syndrome (TAPS) remains poorly researched with few studies have evaluated its optimal management, according to a systematic review published online ahead of print in the journal Supportive Care in Cancer.
TAPS is characterized by myalgias and arthralgias beginning 1 to 3 days and lasting 5 to 7 days after taxane-based chemotherapy.
Although it is known to negatively impact patients’ quality of life, the optimal management of TAPS is unclear.
Therefore, researchers at The Ottawa Hospital and University of Ottawa in Ontario, Canada, conducted a systematic review of treatment strategies for TAPS across all tumor sites.
Results showed that neither glutathione nor glutamine were superior to placebo for TAPS. Researchers found that amifostine, a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy, reduced pain in 36% of patients, while gabapentin reduced taxane-induced arthralgias and myalgias in 90% of patients.
“If the management of patients is to be improved, more prospective trials are needed,” the authors conclude.
Despite its prevalence in patients receiving taxane-based chemotherapies, taxane acute pain syndrome remains poorly researched.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- MRD Negativity Associated With Prolonged Survival in Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|